Log in to your Inderes Free account to see all free content on this page.
Create account

Bioretec

0.02 EUR

-26.67 %

1,738 following
Corporate customer

BRETEC

First North Finland

Medical Equipment & Services

Health Care

-26.67 %
+52.46 %
-47.96 %
-60.11 %
-83.20 %
-88.16 %
-90.46 %
-
-91.50 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
33.19M EUR
Turnover
14.75K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
30.03.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 30.03.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8.5.
2026

General meeting '26

15.5.
2026

Business review Q1'26

13.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
It’s rare to be able to give investment advice, but in this case, one almost dares to suggest: sell the old ones for three cents and buy new ones for a cent.
4/16/2026, 7:28 AM
by Critter
6
You’ve been able to sell them all along since the subscription right split off as its own instrument. By selling immediately, you would have gotten about seven cents for a security worth roughly one cent. Even now, it’s almost 3.
4/16/2026, 7:27 AM
by Expaco_b
4
Getting insurance companies to agree to price a procedure using a biodegradable screw high enough that a financial incentive would be created for the healthcare provider to offer this operation would require a massive lobbying effort. Bioretec’s hope is that a major player who recognizes...
4/17/2026, 7:47 AM
by Clark kent
3
Yeah, and in the US specifically, you’d probably need to be a company in the right spot in the industry food chain so that sales can start moving through a properly oiled machine? My understanding is that a new product has to be almost at the level of a Nobel Prize for the market...
4/17/2026, 6:03 AM
1
Could someone more knowledgeable tell me, as I don’t quite understand how this works. If I have subscribed to the new shares and they are visible in my portfolio, can I already sell the old shares without any impact on the new ones?
4/16/2026, 7:23 AM
by TuuriSeilaaja
1
Couldn’t a procedure performed with Bioretec’s screw be priced high enough that the costs are close to the cost of two traditional operations? Additionally, the patient has an easier time since only one surgical procedure is required. Quality and convenience come at a price.
4/15/2026, 9:29 AM
by Index
1
I was wondering the same thing here already on April 1st, without it even being an April Fool’s joke Luckily I sold the shares back then and bought the subscription rights later…..
4/17/2026, 5:18 AM
by Timo Heikkerö
0
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.